



Marksans Pharma Ltd.

23rd January, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza
BandraKurla Complex
Bandra (E), Mumbai – 400051
Scrip Code: **MARKSANS**

To,
BSE Limited
P. J. Towers
Dalal Street
Mumbai – 400 001
Scrip Code: **524404**

PRESS RELEASE

Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com